These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Anti-VEGF agents in the treatment of neovascular age-related macular degeneration: applying clinical trial results to the treatment of everyday patients. Brown DM; Regillo CD Am J Ophthalmol; 2007 Oct; 144(4):627-37. PubMed ID: 17893015 [TBL] [Abstract][Full Text] [Related]
7. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Ferrara N; Damico L; Shams N; Lowman H; Kim R Retina; 2006 Oct; 26(8):859-70. PubMed ID: 17031284 [TBL] [Abstract][Full Text] [Related]
8. Anatomical benefit from ranibizumab treatment of predominantly classic neovascular age-related macular degeneration in the 2-year anchor study. Sadda SR; Stoller G; Boyer DS; Blodi BA; Shapiro H; Ianchulev T Retina; 2010 Oct; 30(9):1390-9. PubMed ID: 20924261 [TBL] [Abstract][Full Text] [Related]
9. [Future methods of treatment in age related macular degeneration]. Turlea C Oftalmologia; 2012; 56(1):30-5. PubMed ID: 22888684 [TBL] [Abstract][Full Text] [Related]
15. Neovascular age-related macular degeneration: intraocular cytokines and growth factors and the influence of therapy with ranibizumab. Funk M; Karl D; Georgopoulos M; Benesch T; Sacu S; Polak K; Zlabinger GJ; Schmidt-Erfurth U Ophthalmology; 2009 Dec; 116(12):2393-9. PubMed ID: 19815292 [TBL] [Abstract][Full Text] [Related]
16. Targeting VEGF-A to treat cancer and age-related macular degeneration. Ferrara N; Mass RD; Campa C; Kim R Annu Rev Med; 2007; 58():491-504. PubMed ID: 17052163 [TBL] [Abstract][Full Text] [Related]
17. Effect of ranibizumab retreatment frequency on neurosensory retinal volume in neovascular amd. Keane PA; Chang KT; Liakopoulos S; Jivrajka RV; Walsh AC; Sadda SR Retina; 2009 May; 29(5):592-600. PubMed ID: 19289984 [TBL] [Abstract][Full Text] [Related]
18. Anti-macular degeneration agents. Rothen M; Jablon E; Monares G; Fontal MR; Alfaro DV Ophthalmol Clin North Am; 2005 Dec; 18(4):561-7. PubMed ID: 16314219 [TBL] [Abstract][Full Text] [Related]